Difference between revisions of "Cortes JE, et al. Leukemia (2019) cited as Ref 615 in DOI: 10.1038/s41392-020-0110-5 (Q9878)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 33, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 379-389, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (English) | ||
| Property / title: Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 379-389 | ||
| Property / Page(s): 379-389 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Cortes JE, et al. Leukemia (2019) cited as Ref 615 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Cortes JE
0 references
2019
0 references
Leukemia
0 references
33
0 references
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (English)
0 references
379-389
0 references
